(Q41073014)

English

Economic impact of cost-containment strategies in third party programmes in the US (part I).

scientific article published on August 1993

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Economic impact of cost-containment strategies in third party programmes in the US (part I). (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

author name string

C E Reeder

1

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

E W Lingle

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

R M Schulz

3

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

R P Mauch

4

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

B S Nightengale

5

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

C A Pedersen

6

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

M L Watrous

7

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

S E Zetzl

8

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

publication date

1 August 1993

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

92-103

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

https://scigraph.springernature.com/pub.10.2165/00019053-199304020-00004

0 references

The differential impact of copayment on drug use in a Medicaid population

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of current Medicaid prescription reimbursement (MAC/EAC) (maximum allowable cost/estimated acquisition cost) with prescription reimbursement based on a competitive market

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The demand for prescription drugs as a function of cost-sharing.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prescription cost sharing: economic and health impacts, and implications for health policy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Payment restrictions for prescription drugs under Medicaid

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Some interim results from a controlled trial of cost sharing in health insurance

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of medical care in the Rand Health Insurance Experiment. Diagnosis- and service-specific analyses in a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comment on "copayments for ambulatory care: penny-wise and pound-foolish"

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Copayment for pharmaceutical services in a Medicaid program

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Penny-wise and pound-foolish: another look at the data

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of the maximum allowable cost program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Copayments for Ambulatory Care: Penny-Wise and Pound-Foolish

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of a Medicaid drug copayment program on the utilization and cost of prescription services

1 reference

https://pubmed.ncbi.nlm.nih.gov/10146971

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-199304020-00004

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41073014&oldid=1522195476"